These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22112972)

  • 1. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.
    van Oosterwijk JG; Herpers B; Meijer D; Briaire-de Bruijn IH; Cleton-Jansen AM; Gelderblom H; van de Water B; Bovée JV
    Ann Oncol; 2012 Jun; 23(6):1617-26. PubMed ID: 22112972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.
    de Jong Y; van Maldegem AM; Marino-Enriquez A; de Jong D; Suijker J; Briaire-de Bruijn IH; Kruisselbrink AB; Cleton-Jansen AM; Szuhai K; Gelderblom H; Fletcher JA; Bovée JV
    Lab Invest; 2016 Oct; 96(10):1128-37. PubMed ID: 27617402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.
    de Graaff MA; de Rooij MA; van den Akker BE; Gelderblom H; Chibon F; Coindre JM; Marino-Enriquez A; Fletcher JA; Cleton-Jansen AM; Bovée JV
    Br J Cancer; 2016 May; 114(11):1219-26. PubMed ID: 27140314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
    Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
    Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
    Schneiderman RS; Shmueli E; Kirson ED; Palti Y
    BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
    Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
    Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Li R; Zang Y; Li C; Patel NS; Grandis JR; Johnson DE
    Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
    Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells.
    Kim DW; Kim KO; Shin MJ; Ha JH; Seo SW; Yang J; Lee FY
    Mol Cancer; 2009 May; 8():28. PubMed ID: 19445670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma.
    Zhang H; Li M; Han Y; Hong L; Gong T; Sun L; Zheng X
    Dig Dis Sci; 2010 Sep; 55(9):2545-51. PubMed ID: 19960259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
    Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
    Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
    Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
    Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
    Kim EY; Jung JY; Kim A; Chang YS; Kim SK
    Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
    J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation.
    Yan HQ; Huang XB; Ke SZ; Jiang YN; Zhang YH; Wang YN; Li J; Gao FG
    Cancer Sci; 2014 Sep; 105(9):1220-7. PubMed ID: 24988892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.